SCHEMBL14720356

SCHEMBL14720356

CCOC(=O)C(Br)c1ccc(Br)cc1F

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APLNR P35414 4/20 0.42
ALOX5 P09917 4/20 0.40
DGAT1 O75907 1/20 0.39
PTGES O14684 1/20 0.38
MEN1 O00255 1/20 0.38
S1PR4 O95977 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
S1PR1 P21453 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAP2K1 Q02750 1/20 0.38
ALDH1A1 P00352 2/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FPR2 P25090 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19183203 0.86 MAPT (0.44) ALOX5MEN1LMNAMAPTMAPK1
SCHEMBL31192692 0.85 APLNR (0.42) APLNRALOX5DGAT1PTGESMEN1
SCHEMBL14720336 0.84 APLNR (0.47) APLNRDGAT1LMNAMAPTKMT2A
SCHEMBL29149956 0.84 CYP3A4 (0.41) MEN1LMNAS1PR1KMT2AALDH1A1
SCHEMBL8243400 0.82 APLNR (0.43) APLNRALOX5DGAT1PTGESMEN1
SCHEMBL11384531 0.81 ALDH1A1 (0.48) MEN1LMNAMAPTMAPK1KMT2A
SCHEMBL29150011 0.80 PDCD1 (0.39) MAPTNPSR1MAP2K1SMN1; SMN2
SCHEMBL10650360 0.80 PIN1 (0.42) MEN1KMT2AALDH1A1RAB9ASMN1; SMN2
SCHEMBL19914018 0.79 DGAT1 (0.44) APLNRDGAT1LMNAMAPTKMT2A
SCHEMBL8246743 0.78 APLNR (0.42) APLNRALOX5DGAT1PTGESMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744333-B1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-10-05 EP disclosed
US-9084794-B2 Fatty acid synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2015-07-21 US disclosed
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property (No2) Limite (GB) 2014-07-10 US disclosed
EP-2744333-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-06-25 EP disclosed
WO-2013028447-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS2, FADS1 APLNR 907/4885ALOX5 54/4885DGAT1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.